Company intelligence / Profile preview

Magnasense

Ownership: Private
Employees: ~15
Development stage: Commercial

Overview

Magnasense has developed saliva-based diagnostic solutions and digital self-test platforms aimed at both professional and home use. Their main clinical results center on enabling accurate, user-friendly biomarker assays for oral health, chronic disease management, and therapeutic drug monitoring of biologics. The company’s Veritope technology and MagniaReader platform are designed to optimize dosing of biological therapies but no large-scale clinical trial data or regulatory approvals are detailed in public sources.

Therapeutic areas: OtherImmunologyInfectious Diseases
Modalities: Device (diagnostic platform)Biologic (therapeutic drug monitoring focus)
Industry: Protein Biomarker Diagnostics

Partnerships

Not specifically disclosed; collaborates with other pharmaceutical actors in the Nordic region

Beyond the preview

Go deeper on Magnasense.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Magnasense.

Explore the full profile